About GoodCap Pharmaceuticals
GoodCap Pharmaceuticals is a Healthcare company based in Toronto (Canada) founded in 2019 by Irie Selkirk and Darryl Hudson. Psilocybin-based therapeutics for chronic inflammation are developed. It operates on a HealthTech model. GoodCap Pharmaceuticals has raised $49.74 thousand across 1 funding round. The company has 49 employees. GoodCap Pharmaceuticals offers products and services including GCAP001. Its focus areas include Pharmaceuticals and Neuroinflammatory Treatments.
Company details
GoodCap Pharmaceuticals is engaged in the development of innovative medicines for neuroinflammatory disorders, with a primary focus on post-traumatic stress disorder (PTSD). The companys lead drug candidate, GCAP001, is designed to reduce inflammatory biomarkers associated with psychiatric and neurodegenerative conditions. Solutions are developed to address unmet needs in mental health and neurological care, targeting broad symptomology in affected populations. The organization operates within the healthcare and pharmaceutical sectors, aiming to provide safer and more effective therapeutic options.
- Headquarters Toronto, Canada
- Employees 49
- Founders Irie Selkirk, Darryl Hudson
- SectorsHealthcare
- Email••••••••
- Website goodcap.com
- Social LinkedIn X
- Legal Name Goodcap Pharmaceuticals
- Total Equity Funding$49.74K (USD)
in 1 rounds
- Latest Funding Round$49.74K (USD), Seed
Dec 2024
- Employee Count49
Products & Services of GoodCap Pharmaceuticals
GoodCap Pharmaceuticals offers a comprehensive portfolio of products and services, including GCAP001.
Lead drug candidate targeting neuroinflammatory disorders like PTSD.
Funding Insights of GoodCap Pharmaceuticals
GoodCap Pharmaceuticals has successfully raised a total of $49.74K through 1 strategic funding round. The most recent funding activity was a Seed round of $49.74 thousand completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $49,737
- Total Rounds 1
- Last Round Seed — $49,737
- First Round $49,737
(Dec 2024)
All 1 funding rounds of GoodCap Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $49,737 | Seed | – | – | – |
People of GoodCap Pharmaceuticals
2 people are tracked at GoodCap Pharmaceuticals (2 in leadership); the tracked headcount is 49.
| Name | Role | Group |
|---|---|---|
Irie Selkirk | ex-Co-Founder | Leadership |
Darryl Hudson | Co-Founder | Leadership |
Complete people profiles for GoodCap Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GoodCap Pharmaceuticals
2 dated milestones of GoodCap Pharmaceuticals across 5 years, from founding to its latest funding, stage changes and deals.
- Founded GoodCap Pharmaceuticals is founded.
- Funding First funding round of $50K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GoodCap Pharmaceuticals
GoodCap Pharmaceuticals was founded in 2019 and raised its 1st funding round 5 years after it was founded.
GoodCap Pharmaceuticals is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
GoodCap Pharmaceuticals is a funded company, having raised a total of $49.74K across 1 funding round to date. The company's 1st funding round was a Seed of $49.74K, raised on Dec 2024.
GoodCap Pharmaceuticals has 49 employees.
GoodCap Pharmaceuticals is engaged in the development of innovative medicines for neuroinflammatory disorders, with a primary focus on post-traumatic stress disorder (PTSD). The companys lead drug candidate, GCAP001, is designed to reduce inflammatory biomarkers associated with psychiatric and neurodegenerative conditions. Solutions are developed to address unmet needs in mental health and neurological care, targeting broad symptomology in affected populations. The organization operates within the healthcare and pharmaceutical sectors, aiming to provide safer and more effective therapeutic options.
GoodCap Pharmaceuticals offers GCAP001.
GoodCap Pharmaceuticals operates through Goodcap Pharmaceuticals.